ALLEGAN, Mich., Feb. 14, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to Schering-Plough's Claritin-D® 12 hour extended release tablets.
Claritin-D® 12 is indicated for the treatment of nasal allergy symptoms. Its estimated annual sales are approximately $111 million, according to data provided by Wolters, Kluwer.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This launch is another milestone for our Consumer Healthcare segment, which is expected to launch many important new store brand products during this fiscal year. We are excited to bring this important store brand medication to consumers for the first time and continue our focus on making quality healthcare more affordable."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activit
|SOURCE Perrigo Company|
Copyright©2010 PR Newswire.
All rights reserved